๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II Trial of CI-958 in Recurrent Platinum-Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study

โœ Scribed by Mark A. Hoffman; John A. Blessing; Mark Morgan

Book ID
112248288
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
34 KB
Volume
79
Category
Article
ISSN
0090-8258

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II evaluation of three-day topotec
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma : A Gynecologic Oncology Group study
โœ David Scott Miller; John A. Blessing; Samuel S. Lentz; D. Scott McMeekin ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 79 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Topotecan, administeredintravenously at a dose of 1.5 mg/m^2^ per day for 5 days every 21 days, is an established regimen in the treatment of recurrent ovarian carcinoma. Alternate dosing strategies have sought to improve toxicity. The authors evaluated the tolerability a